Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tango Therapeutics (TNGX) Operating Expenses (2020 - 2025)

Historic Operating Expenses for Tango Therapeutics (TNGX) over the last 6 years, with Q3 2025 value amounting to $39.7 million.

  • Tango Therapeutics' Operating Expenses fell 1066.88% to $39.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $176.8 million, marking a year-over-year decrease of 341.16%. This contributed to the annual value of $187.7 million for FY2024, which is 2452.82% up from last year.
  • Per Tango Therapeutics' latest filing, its Operating Expenses stood at $39.7 million for Q3 2025, which was down 1066.88% from $44.1 million recorded in Q2 2025.
  • Over the past 5 years, Tango Therapeutics' Operating Expenses peaked at $49.4 million during Q2 2024, and registered a low of $18.5 million during Q1 2021.
  • For the 5-year period, Tango Therapeutics' Operating Expenses averaged around $36.9 million, with its median value being $37.0 million (2022).
  • As far as peak fluctuations go, Tango Therapeutics' Operating Expenses skyrocketed by 481112881.36% in 2021, and later crashed by 1068.04% in 2025.
  • Quarter analysis of 5 years shows Tango Therapeutics' Operating Expenses stood at $27.7 million in 2021, then skyrocketed by 33.49% to $37.0 million in 2022, then rose by 9.37% to $40.4 million in 2023, then increased by 11.33% to $45.0 million in 2024, then dropped by 11.74% to $39.7 million in 2025.
  • Its Operating Expenses stands at $39.7 million for Q3 2025, versus $44.1 million for Q2 2025 and $47.9 million for Q1 2025.